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Introduction
Alpha-1-antitrypsin deficiency (AATD) is a
potentially lethal genetic disorder, characterized by
serum concentrations of alpha-1-antritrypsin (AAT)
lower than 0.5 mg/L, which has liver and pulmonary
manifestations (1, 2). From a clinical laboratory point
of view, the standardized biochemical and molecular
diagnostic protocol for detection of clinically relevant
alleles in a timely and cost-effective manner is needed
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Kratak sadr`aj: Nedostatak alfa-1-antitripsina je poten ci -
jalno smrtonosan genetski poreme}aj sa pulmonarnim i
hepa ti~nim manifestacijama. Uo~ljiva je potreba za stan -
dardi zovanim protokolom detekcije klini~ki zna~ajnih alela,
koji bi uklju~ivao biohemijske i molekularne metode. Rad
prikazuje savremena shvatanja o nedostatku alfa-1-anti -
tripsina, opisuje mogu}nosti primene izoelektrofokusiranja
i testa zasnovanog na kombinaciji PCR amplifikacije i
reverzne hibridizacije sa alel-specifi~nim oligonukleotidima
i ukratko opisuje na{a iskustva u toj oblasti dijagnostike.
Mo`e se zaklju~iti da bi, u klini~kim laboratorijama, kombi -
na cija dveju pomenutih metoda, uz dodatne informacije
do bijene kvantitativnom analizom, mogla predstavljati
osno vu detekcije genetski uslovljenog nedostatka alfa-1-
antitri p sina. Neophodno je naglasiti da je za sveobuhvatnu
medi cin sku primenu takvog laboratorijskog protokola ne -
opho dna saradnja medicinskih biohemi~ara, moleku lar nih
biologa i lekara odgovornih za le~enje bolesnika sa genet -
ski uslovljenim nedostatkom alfa-1-antitripsina.
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Summary: Alpha-1-antitrypsin deficiency is a potentially
lethal genetic disorder, which has pulmonary and liver
manifestations. The standardized biochemical and mole -
cular diagnostic protocol for detection of clinically relevant
alleles is needed. The paper summarizes current concepts
about AATD, describes the potentials of isoelectric focusing
and PCR amplification-reverse allele specific oligonucleo -
tide hybridization assay in the detection of affected indivi -
duals and shortly presents our experiences in the evaluation
of AATD. We conclude that the systematic clinical labo -
ratory approach to AATD might be based on the combi -
nation of men tioned methods, coordinated by alpha-1-
antritrypsin quantification. Additionally, its complete
medical imple men tation is achieved through teamwork
between clinical che mists, molecular biologists and clini -
cians.
Keywords: isoelectrofocusing, PCR-reverse hybridi za tion,
alpha-1-antitrypsin
Non-standard abbreviations: AATD – alpha-1-antitrypsin
deficiency, AAT – alpha-1-antitrypsin, NE – neutrophil ela sta se,
PR-3 – proteinase, HNP – human neutrophil peptide, eNOS
– endothelial nitric oxide synthase, GSTP1 – glutat hione S
transferase 1 gene, ANCA – anticytoplasmatic anti body, ER –
endoplasmatic reticulum, PSM – PCR-mediated site direction
polymorphism, RFLP – restriction fragment length polymor -
phism, ASO – allele specific oligonu cleo tides, SSCP – single
stranded conformation polymorphism, DGGE – denaturating
gradient gel electrophoresis, RT-PCR – real time PCR, COPD
– chronic obstructive pulmonary disease.
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(3). This paper summarizes the current concepts about
AATD, describes the potentials of isoelectric focusing
and the PCR amplification-reverse hybridi zation assay
in the detection of affected individuals and shortly
presents our experiences in the evaluation of AATD.
Alpha-1-antitrypsin deficiency 
Alpha-1-antitrypsin is the archetype of the
serpin superfamily, the members of which control
many inflam matory cascades, mainly through tightly
grasping and inhibiting serine proteases, such as
neutrophil elastase (NE), cathepsin G and proteinase
3 (PR-3) (3, 4). It is a single-chained glycosylated
protein with a molecular mass of ≈51 kDa. The AAT
synthesis occurs primarily in the liver (5), although it
can be evi denced in the lung, macrophages, renal
paren chymal cells and intestinal epithelium (1, 4). 
From a physiological viewpoint, AAT represents
a major defense against the elastolytic burden in the
lower respiratory tract, owing to its ability to inhibit
NE. Additional antiinflammatory effects, unrelated to
NE inhibiton, have also been reported (eg. blockage
of the proinflammatory effects of HNP and regulation
of cytokine expression) (2). The most important sti -
mulators of AAT synthesis and the consequent increase
in plasma concentrations are acute phase response
and estrogens. Plasma AAT levels are decreased with
genetic deficiency, increased use and urinary or
gastro intestinal loss (5). 
The AAT is encoded by the gene located on
chromosome 14q31, which is 122 kb in length and
has seven exons and six introns. The available data
suggest that the AATD is inherited in a co-dominant
fashion. The gene is highly polymorphic, with more
than 120 PI (Protease Inhibitor) identified alleles, which
can be classified as: normal (M (various subtypes), X
Christchurch), deficient (Z, S, Mmalton, Siiyama, Mheerlen, Mpro -
cida, Mmineral springs), null (QOgranite falls, QOludwigshafen,
QOhongkong 1, QOisola di procida) and dysfunctional alleles
(Pittsburgh, Mmineral springs, Z). The polymorphic features
of the AAT gene may lead to the AATD by
abnormalities in gene expression, translation and
intracellular protein processing (6). The Z and S
alleles are the two most frequent and clinically the
most important deficient alleles. The Z allele consists
of a lysine-to-glutamate substitution at codon 366
(E366K), while the S variation represents a substi -
tution of valine for glutamate at codon 288 (E288V).
Normal alleles are related to normal AAT concen -
tration in the serum of 0.8–2.2 g/L (2). Carriers of
the Z allele usually have only 15% of normal AAT
blood concentration in homozygous and 60–75% in
hetero zygous state (7). The S allele gives 60% of
normal AAT concentration in homozygous and up to
80% in heterozygous carriers (8, 9). The mean gene
frequency of Z allele is 0.014, with the highest
prevalence in Northern Europe and populations with
North European background, while the S has the
mean gene frequency of 0.056, with the peak in the
Iberian peninsula (9, 10). Worldwide estimations
speculate with the numbers 116 000 000 for the
carriers of deficient alleles and 1 100 000 for subjects
with severe AATD (11).
Molecular pathology associated with the Z allele
comprises both toxic gain-of- and functional loss-of-
function (1). Due to the mutation, the tertiary
structure of AAT is distorted and the reactive loop of
one molecule interlocks with the b pleated sheet of
another, forming fibril-like polymers. Further polyme -
rization leads to the formation of insoluble inclusions,
which trigger ER stress and represent hallmarks of
AAT liver disease (1, 4, 7, 12). This feature classifies
Z-associated AATD as the paradigm of conforma -
tional diseases (1). Intracellular accumulation
releases only 15% of the synthesized protein into the
circulation, so the anti-protease protection on the
airway epithelial surface is consequently decreased
and an uncontrolled proteolytic attack is allowed (1,
3, 4, 7). Additionally, polymerization of AAT locally
produced in the lung is evidenced to engrave
pulmonary manifestations and limits local admini -
stration of augmentative therapy (4). In the case of S
variant, the decreased AAT concentration results in
misfolding and increased degradation of molecule
within the hepatocytes, while the intracellular accu -
mulation is absent (4). The gene-enviromental
interactions give a significant contribution to the
formation of the »AATD clinical phenotype«. Among
them, the most important are: smoking, exposure to
dust and inhalants, comorbidities (eg. asthma,
sarcoidosis) and other genetic polymorphisms (eg.
eNOS, GSTP1) (6, 13). 
Concerning its clinical manifestations, AATD can
be described as a conformational disease which
primarily predisposes to lung (eg. emphysema and
bronchiectasis) and liver (eg. chronic hepatitis,
cirrhosis, hepatoma) disorders (1, 2, 4). The other well
established disease associations include skin disease,
such as panniculitis, and ANCA positive vasculitis (1,
4). The connections between AATD and some other
diseases (eg. glomerulonephritis, coliac disease, cancer
(lung, colorectal and bladder loca lizations), intracranial
and intra-abdominal aneurysms) are postulated, but
need further evaluation and clarification (2, 3). The
distinctive and suggestive features of emphysema
associated with AATD comprise early onset (ie. 30–40
years), panacinar pathology and disproportionate
emphysematous involvement of the lung bases (2, 3).
Bronchiectasis is recognized in AATD, but data are
limited concerning their frequency, type and
manifestations (2, 14). The most frequent genotype
among individuals with lung disease due to AATD is ZZ
(more than 95%), while the second in order of
frequency is SZ (2). Hepatic manifestations of AATD
usually occur in children (prolonged jaundice,
increased liver enzyme activity, hepatosplenomegaly,
bleeding tendency) or in the 6th decade of life (chronic
liver disease, cirrhosis, hepa tocellular carcinoma). They
are mostly associated with the homozygous presence
of Z or Mmalton alleles or their mutual presence in
heterozygous genotypes. It is not common for the
same individual to have both the hepatic and
pulmonary disease due to the AATD (1, 2, 4).
Therapy of AATD includes environmental mea -
 sures, primarily smoking cessation, nonspecific med i cal
treatment and specific measures, according to the
predilection site of manifestations of AATD (4). The
augmentation therapy, administered intravenously or
by inhalation, is successful in the treatment of patients
with lung manifestations. The potential use of reti noids,
hyaluronic acid, antioxidants as well as gene therapy is
under investigation. In AATD patients with liver disease
liver transplantation is currently the only effective
means of intervention, but its efficiency is diminished
by a lack of suitable donors and need for immuno -
suppressive therapy. New therapeutic stra te gies might
include chemical chaperones, synthetic anti-poly meri -
zation peptides and gene therapy (1, 2, 4). 
Identification of individuals affected by AATD
may provide substantial health benefits in the form of
opportunities to receive augmentative therapy and to
minimize environmental risk factors (smoking, occu -
pational hazards) (15, 16). According to the current
recommendations, the AATD should be evaluated in
subjects presenting with emphysema with early-onset
(age of 45 years or less), absence of a recognized risk
factor (smoking, occupational dust exposure, etc.) or
with prominent basilar hyperlucency, unexplained
liver disease, necrotizing panniculitis, ANCA-positive
vasculitis, family history of any of the following:
emphysema, bronchiectasis, liver disease, or panni -
culitis, bronchiectasis without evident etiology (17).
Important issues concerning AATD are screening
strategies. Neonatal screening is abandoned, due to
the presence of serious disadvantages including
psychosocial issues and discrimination. A precisely
balanced definition of the adult population to be
screened is a prerequisite for successful screening, in
order to avoid limitations seen both in large popu -
lation-based screening and in small targeted
detection programs in high risk groups (4, 17).
Laboratory methods for 
the evaluation of AATD
The first laboratory approach to AATD com -
bined paper electrophoresis, agar-gel electrophoresis
and immunoelectrophoresis, while the multiallelic
nature of the PI locus was confirmed using starch-gel
ele c trophoresis (18). The identification of PI pheno -
types was further improved by the application of iso -
electrofocusing methods (19–21). The information
about AAT-coding DNA sequence, provided by
cloning and DNA sequencing, enabled detailed cha -
racterization of known and new AAT variants, on the
protein and gene level (18, 22–24). Comprehensive
laboratory testing can be divided into four stages:
quantification, phenotyping, genotyping and evalu -
ation of AAT function (3, 17). 
Quantitative analysis, which measures the
»level« of AAT in serum or plasma, is the first test to
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Figure 2 Genotyping of AAT using PCR amplification and reverse ASO hybridization. The text at the left side is the instruction
from the reading card.
Conjugate Control (CC)
Specificity Control (Spec-C)
Specificity Control MZ (Sens-MZ)
Pi M
Pi Z
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Figure 1 Isoelectrofocusing of various AAT variants in the
pH range 4.2-4.9 after Coomassie Brilliant Blue staining
(anode at top).
be performed when an individual is suspected for
AATD. Clinical laboratories almost exclusively
perform immunonephelometric methods, which are
reliable, inexpensive and subject to automation (3, 5).
The main constrain of AAT quantification is that it is
not sufficient to confirm the genetic cause of AATD.
The obtained concentrations might be elevated due to
inflammation or injury, or reduced by causes such as
liver damage or protein-losing enteropathies. Never -
theless, the AAT level is an important feature of  the
protocol for detecting AATD (eg. indicator for reflex
tests) and clinical evaluation of AATD (3, 5, 25). 
The potentials and constraints of isoele ctrofo cu -
sing as a laboratory tool for AATD detection will be
discussed later.
Molecular approach to AATD evaluation enco m -
passes methods for detection of the Z and S alleles,
as clinically the most relevant ones, and DNA
sequencing. Unambiguous diagnosis of Z and S
variants can be achieved at a molecular level using
PCR-PSM, PCR-RFLP, ASO hybridization, SSCP,
DGGE and RT-PCR methods. Although expensive and
time-consuming, DNA sequencing methods are
needed, concerning the diversity of AATD symptoms
and the questionable reliability of phenotyping
methods in some situations (18, 26–28). Genotyping
in routine clinical laboratories may be facilitated by
the use of commercially available test kits. Such an
approach is offered by the method combining PCR
amplifi cation with allele specific oligonucleotide
hybridi zation (29, 30), which will be discussed later.
The inhibitory function of AAT can be evaluated
using a semiquantitative assay which measures serum
inhib ition of trypsin or elastase against small sub strates.
However, this test is not specific for AATD, con cerning
the presence of other serpins in serum (3, 5). 
A standardized laboratory protocol for AATD
detection must be adapted for use of both standard (ie.
obtained by venipuncture) and alternative samples (ie.
dried blood spots). This issue appears rather important,
because many AATD detection programs perform all
types of necessary analyses from whole blood drops
absorbed on special filter paper (3). 
Isoelectrofocusing in AATD evaluation
Isoelectrofocusing or isoelectric focusing (IEF) is
an electrophoretic method for the separation of
amphoteric molecules, according to their isoelectric
points (pI). The separation is achieved in stabilized and
continuous pH gradient, with regular and con stant
conductivity and buffer capacity. The technique can be
carried out on polyacrylamide or agarose gels. The pH
gradient is formed in the electric field by the carrier
ampholytes (both kinds of gels) or by immobilized pH
gradients, in which the buffering groups are part of the
medium (only polyacrylamide gels). The main area of
IEF application is the identi fication of genetic variants
and investigation of phy sico-chemical and biological
influences on proteins and hormones, although it can
be employed for preparative purposes (31). Analytical
IEF can be carried out in capillary electrophoresis
equipment, what makes it a very important tool for
quality assu rance of biopharmaceutics and also for
proteome analysis, especially if coupled with mass
spectro meters (32).
The phenotyping of AAT in serum by IEF is
recommended as a gold standard for laboratory
confirmation of AATD. The test is recommended for
individuals with a decreased level, detected by immu no -
nephelometry, or in situations when high index of
clinical suspicion for AATD persists although AAT are
not below the lower reference limit (15, 17). Clinical
laboratories perform the test on precasted, narrow-
pH-gradient (pH 4-5), thin-layer polyacryl amide gels.
A gel pattern with the typical microheterogenity of
some common AAT variants of clinical importance is
made visible by Coomassie Brilliant Blue staining. The
phenotype associated with the homozygous presence
of normal alleles consists of two major and three
minor bands, whose presence is due to the various
syalic acid contents and the length of chain. If deficient
alleles are present, some bands have altered mobility,
while some are not visible. In each IEF run, a sample of
the MZ heterozygote, confirmed by an alternative
independent method, should be applied as a marker of
phenotyping and for quality control. In the case of PI
phenotyping from stored and frozen-thawed samples, a
reduction with cysteine is recommended as the
pretreatment. Phenotypes must be identified by two
persons independently, and in any case of discordance
the test is repeated (33, 34). Figure 1 demonstrates a
gel pattern obtained in our laboratory.
The application of IEF in the evaluation of AATD
has several limitations. Concerning technical diffi -
culties, it must be highlighted that IEF is a challenging
procedure, which requires highly skilled personnel.
Rather often, errors in PI phenotyping are due to poor
sample quality or iatrogenic causes (ie. sample taken
from patient receiving AAT augmentation therapy).
Finally, interpretation of the gels is the most challen -
ging aspect, because of the complex microhete ro -
genity of AAT and the large number of variants (25). 
PCR amplification-reverse allele 
specific oligonucleotide hybridization
assay in AATD evaluation 
(PCR-reverse ASO hybridization)
The allele specific oligonucleotide (ASO)
hybridization is a very reliable method to detect
mutations involving single base changes and small
deletions. The method is based upon the ability of the
single stranded short oligonucleotide to hybridize with
completely complementary single stranded target
DNA. A mutation, even in a single nucleotide will
abolish hybridization. The ASO hybridization can be
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applied as forward and reverse. The principle of the
forward ASO hybridization is the binding of target DNA
onto solid membranes, and subsequent denaturation
and hybridization to labelled oligonucleotide probe. In
the reverse ASO hybridization, the tailed single
stranded oligonucleotides, with a poly dT tail at the 3’
end, are covalently attached to the solid phase and the
amplified target DNA is then hybridized with immobi -
lized oligonucleotides. A lebel is incorporated into PCR
reaction to make the bound PCR product visible (29).
The detection of the Z and S AAT alleles, using
a commercial kit which combines PCR amplification
and reverse ASO hybridization, is achieved through
the following steps: DNA isolation from a patient
sample, multiplex amplification with biotinylated
primers and reverse hybridization. Blood samples for
DNA isolation can be collected with EDTA or citrate,
while the samples collected with heparin can be used
after the additional pretreatment. The hybridization
includes the following steps: chemical denaturation of
the amplification products, hybridization of the single-
stranded, biotin-labelled amplicons to membrane-
bound probes, stringent washing, addition of a
streptavidin/alkaline phosphatase (AP) conjugate,
and an AP mediated staining reaction. A reading card
ensures the easy and fast interpretation of the
banding pattern obtained (30, 35). Figure 2 shows
banding patterns obtained in our laboratory.
The advantages offered to the clinical laboratory
by the above described methodology are numerous.
The assay, structured as a multiplex test, provides
simultaneous, unambiguous determination of both Z
and S alleles. The whole procedure is not time-
consuming and requires a minimum of expertise in
the molecular biology techniques. The main limita -
tion, shared by other allele-specific assays for the Z or
S AAT mutations, is that the assay provides no
evidence for the alleles other than M, Z and S (30). 
The interplay of IEF and PCR-reverse
ASO hybridization assay in AATD
evaluation 
After consideration of the previously mentioned
advantages and disadvantages of both methods, it
can be stated that IEF and the PCR-reverse ASO
hybridization assay for AAT are complementary
methods. Consequently, the laboratory approach to
AATD has to be modified to meet the challenges
concerning the presentation of obtained data in
clinically useful format. The combination of quanti -
fication and genotyping by the PCR-reverse ASO
hybridization assay are prompted to be used as the
first level of testing. The IEF is mandatory in all situa -
tions when serum AAT concentrations do not
correlate with the determined genotype or clinical
findings. Considering the numerous physiologic and
pathological conditions influencing AAT concen tra -
tions, in the majority of cases phenotyping is expected
to confirm the genotype result. The IEF, as the reflex
test in such situations allows for more confidence in
the resulting diagnosis. The real importance of IEF as
a reflex test is conferred by its ability to suggest the
presence of a null allele or rare deficiency variants
(eg. Mmalton, Siiyama, Mmineral springs, QOisola di procida), in
ho mo zygous state or in combinations with M, Z and
S alleles. In such cases the final evaluation of genetic
causes of AATD is given by DNA sequencing done in
specialized molecular biology laboratory (25, 36).
The combination of quantification, detection of the Z
and S allele by targeted genotyping  and phenotyping
is generally accepted by screening programs in the
United States and most of the European countries with
established AATD National Registers (25, 37, 38).
Our recent experiences in AATD
evaluation
The frequency of Z allele in the Serbian popul a -
tion (0.013) is comparable to that in the populations
of Central Europe, while the S allele frequency
(0.0066) is the lowest among the populations of
Europe, except for the Finish (39, 40). 
Since January 2007, we evaluated AATD in 42
adults and 3 newborns. The main clinical features
which prompted for AATD evaluation in adults were:
COPD (22 patients), emphysema (9 patients), pneu mo -
thorax (3 patients), pulmonary infiltration (1 patient),
asthma (1 patient) and bronchiectasis (1 pa tient).
Familial testing was conducted in four cases. We
confirmed 2 cases of severe AATD, associated with the
homozygous presence of the Z allele. The presence of
MZ phenotype was detec ted in 7 adults. Surprisingly, in
three MZ carriers, the AAT concen tration was normal,
but this increase was attributed to inflammation,
evidenced by an elevated level of CRP. This finding
highlights the need for phenotyping despite the normal
AAT concen tration, in cases which are highly clinically
suspicious. The new borns were referred for AATD
evaluation due to the pre sence of prolonged jaundice
and chole stasis. Among them, one carrier of the MZ
phenotype was identified.
Conclusion
The combination of IEF and PCR-reverse ASO
hybridization, coordinated by AAT quantification,
offers a systematic clinical laboratory approach to
AATD evaluation. Through teamwork between
clinical chemists, molecular biologists and clinicians
we can best achieve the shift of the AATD medical
focus from treatment to prevention.
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